Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when NRIX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsNurix holds routine 2026 Annual Meeting, elects three directors with 81% quorum
Filed May 15, 2026 · Period ending May 15, 2026 · ~1 min read
Key Changes
-
low
Three Class III directors elected to serve until 2029: Arthur T. Sands, Roger Dansey, and Paul M. Silva, all receiving majority stockholder support with approximately 81% of voting shares represented at the meeting.
Item 5.07 verify on EDGAR → -
low
Stockholders ratified PricewaterhouseCoopers LLP as independent auditor for fiscal 2026 with 83.6 million votes in favor, representing strong approval to continue the existing auditor relationship.
Item 5.07 verify on EDGAR → -
low
Executive compensation received stockholder approval in advisory vote, confirming support for the company's compensation practices as detailed in the March 27, 2026 proxy statement.
Item 5.07 verify on EDGAR →
Summary
Nurix Therapeutics held its 2026 Annual Meeting of Stockholders on May 15, 2026, as a virtual-only event. With approximately 81% of voting shares represented, stockholders approved all three proposals on the ballot. The meeting resulted in the election of three Class III directors to three-year terms expiring in 2029, ratification of PwC as the company's auditor, and approval of executive compensation practices.
For retail investors, this is a routine procedural filing with no material business impact. The strong quorum and approval rates indicate general stockholder satisfaction with current governance and management. The election results show broad support for all three directors, though Paul Silva received notably more withhold votes than the other nominees. Investors should watch for Nurix's upcoming fiscal 2026 year-end results and any pipeline updates, as this filing contains no information about the company's drug development programs or financial performance.
Section-by-Section Diff
Event · Item 5.07 — Submission of Matters to a Vote of Security Holders
Nurix held its 2026 Annual Meeting on May 15, 2026, where stockholders elected three Class III directors, ratified PwC as auditor, and approved executive compensation.
Show 2 minor / wording changes
Added in current filing · verify on EDGAR →
On May 15, 2026, Nurix Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders exclusively online via live webcast (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on three proposals, each of which is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on March 27, 2026 (the “Proxy Statement”). There were 83,747,013 shares of common stock present at the Annual Meeting in person or by proxy, which represented approximately 80.98% of the voting power of the shares of common stock entitled to vote at the Annual Meeting and constituted a quorum for the transaction of business.
Nurix held its annual stockholder meeting on May 15, 2026, with approximately 80.98% of voting shares represented. Stockholders voted on three proposals: director elections, auditor ratification, and executive compensation approval. All three proposals passed.
Added in current filing · verify on EDGAR →
Arthur T. Sands, M.D., Ph.D.63,592,94816,334,5703,819,495 Roger Dansey, M.D.79,607,489320,0293,819,495 Paul M. Silva 59,298,61220,628,9063,819,495 Each of the three nominees for director was elected to serve until the Company’s 2029 annual meeting of stockholders and until his successor has been elected and qualified, or until his earlier resignation or removal.
Three Class III directors were elected to three-year terms expiring in 2029: Arthur T. Sands, Roger Dansey, and Paul M. Silva. All three nominees received majority support, with Dr. Dansey receiving the strongest support (79.6 million votes for) and Mr. Silva receiving the most withhold votes (20.6 million).
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 9, 2026 · How we verify